HoLEP vs BPRP of a Large Volume BPH: a Randomised Controlled Trial

October 26, 2019 updated by: Mohammed Said ElSheemy, Cairo University

Holmium Laser Enucleation vs Bipolar Resection of a Large Volume BPH: a Randomised Controlled Study

To compare bipolar resection versus holmium laser enucleation for management of large BPH.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

To compare safety and efficacy of bipolar resection (BPRP) versus holmium laser enucleation (HoLEP) for management of large BPH (> 75 gm).

Study Type

Interventional

Enrollment (Actual)

145

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Cairo, Egypt, 12222
        • Cairo University Hospitals

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Patients suffering from LUTS secondary to infravesical obstruction from BPH
  • failed medical treatment
  • International Prostate Symptom Score (IPSS) > 13
  • a peak urinary flow rate (Qmax) < 15 ml/sec
  • a prostate size ≥ 75 gm

Exclusion Criteria:

  • presence of a urethral stricture
  • neurological disorder
  • bladder cancer
  • prostate cancer
  • previous history of bladder neck surgery or TURP

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: holmium laser enucleation of the prostate
holmium laser enucleation of the prostate (HoLEP)
Procedure: holmium laser enucleation of the prostate
cystoscopic transurethral enucleation of the prostate using Holmium laser (Versa pulse 100W; Lumenis; Germany)
Other Names:
  • HoLEP
ACTIVE_COMPARATOR: bipolar resection of the prostate
bipolar resection of the prostate (BPEP)
Procedure: Bipolar resection of the prostate
cystoscopic transurethral resection of the prostate using bipolar energy
Other Names:
  • BPRP

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
hemoglobin drop postoperatively (gm/dL)
Time Frame: Immediate postoperatively
difference in hemoglobin concentration postoperatively vs preoperatively
Immediate postoperatively
operative duration in minutes
Time Frame: during surgery
operative duration
during surgery
Hospital stay in days
Time Frame: immediately after surgery
Hospital stay
immediately after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
complications (%)
Time Frame: Two years
intraoperative and postoperative complications including blood transfusion, capsular perforation, irritative symptoms, SUI, urethral stricture, bladder neck contracture, urinary retention.
Two years
urine flow
Time Frame: Two years
Qmax (ml/s),
Two years
post-voiding residual urine
Time Frame: Two years
postvoiding residual urine (ml)
Two years
International prostate symptom score (IPSS)
Time Frame: Two years
an international commonly used score ranging from 0 - 35 (the worst is 35) evaluating voiding and storage urinary symptoms using 7 questions each one is scored from 0 to 5 according to severity of symptom
Two years
Quality of life (QoL)
Time Frame: Two years
section of International prostate symptom score (IPSS) one question scored from 0 up to 6 (6 is worst)
Two years
Catheter duration
Time Frame: immediate postoperatively
Catheter duration in hours
immediate postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Investigators

  • Study Director: enmar I Habib, Cairo University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 14, 2016

Primary Completion (ACTUAL)

May 1, 2019

Study Completion (ACTUAL)

June 10, 2019

Study Registration Dates

First Submitted

October 26, 2019

First Submitted That Met QC Criteria

October 26, 2019

First Posted (ACTUAL)

October 29, 2019

Study Record Updates

Last Update Posted (ACTUAL)

October 29, 2019

Last Update Submitted That Met QC Criteria

October 26, 2019

Last Verified

October 1, 2019

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 62513

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Male

Clinical Trials on Bipolar resection of the prostate

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe